{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "GBp", "marketState": "POSTPOST", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "esgPopulated": false, "regularMarketChangePercent": 4.0650406, "regularMarketPrice": 3.2, "exchange": "LSE", "shortName": "GENFLOW BIOSCIENCES PLC ORD GBP", "longName": "Genflow Biosciences plc", "messageBoardId": "finmb_1763803753", "exchangeTimezoneName": "Europe/London", "market": "gb_market", "regularMarketTime": 1683905727, "regularMarketDayHigh": 3.2, "regularMarketDayRange": "2.85 - 3.2", "regularMarketDayLow": 2.85, "regularMarketVolume": 234503, "regularMarketPreviousClose": 3.075, "bid": 2.95, "ask": 3.2, "fullExchangeName": "LSE", "financialCurrency": "GBP", "regularMarketOpen": 3.05, "averageDailyVolume3Month": 1894249, "averageDailyVolume10Day": 1113547, "fiftyTwoWeekLowChange": 1.7750001, "fiftyTwoWeekLowChangePercent": 1.2456142, "fiftyTwoWeekRange": "1.425 - 7.5", "fiftyTwoWeekHighChange": -4.3, "fiftyTwoWeekHighChangePercent": -0.5733334, "fiftyTwoWeekLow": 1.425, "fiftyTwoWeekHigh": 7.5, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.0, "sharesOutstanding": 292507008, "bookValue": 0.01, "fiftyDayAverage": 2.694, "fiftyDayAverageChange": 0.50600004, "fiftyDayAverageChangePercent": 0.18782482, "twoHundredDayAverage": 2.551775, "twoHundredDayAverageChange": 0.64822507, "twoHundredDayAverageChangePercent": 0.2540291, "marketCap": 12130848, "priceToBook": 320.0, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1642406400000, "priceHint": 4, "regularMarketChange": 0.125, "symbol": "GENF.L"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "15 Ingestre Place", "address2": "Suite 1", "city": "London", "zip": "W1F 0DU", "country": "United Kingdom", "phone": "44 32 4774 95881", "website": "https://genflowbio.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Genflow Biosciences plc operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing or halting the ageing process, and reducing the incidence of age-related diseases with increase in health span. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. The company was incorporated in 2021 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 2, "companyOfficers": [{"maxAge": 1, "name": "Dr. Eric Jean Leire M.D., MBA", "age": 64, "title": "Founder, CEO & Exec. Director", "yearBorn": 1958, "fiscalYear": 2021, "totalPay": {"raw": 148017, "fmt": "148.02k", "longFmt": "148,017"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Cedric  Szpirer", "title": "Head of CMC", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}